LILRA3 siRNA (Human)

SiRNA to inhibit LILRA3 expression using RNA interference

Product Specifications

Product Name Alternative

ILT6; LIR4; Leukocyte immunoglobulin-like receptor subfamily A member 3; CD85 antigen-like family member E; Immunoglobulin-like transcript 6; ILT-6; Leukocyte immunoglobulin-like receptor 4; LIR-4; Monocyte inhibitory receptor HM43/HM31; CD antigen CD85e

Reactivity

Source

Synthetic

Applications

RNAi

Purity

> 97%

Form

Lyophilized powder

Components

We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of human LILRA3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.

Storage Conditions

Shipped at 4 °C. Store at -20 °C for one year.

Specificity

LILRA3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

NCBI Gene Symbol

LILRA3

Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.